Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease

Faiz Ul Amin, Ali Kafash Hoshiar, Ton Do, Yeongil Noh, Shahid Ali Shah, Muhammad Sohail Khan, Jungwon Yoon, Myeong Ok Kim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disease, pathologically characterized by the accumulation of aggregated amyloid beta (Aβ) in the brain. Here, we describe for the first time the development of a new, pioneering nanotechnology-based drug delivery approach for potential therapies for neurodegenerative diseases, particularly AD. We demonstrated the delivery of fluorescent carboxyl magnetic Nile Red particles (FMNPs) to the brains of normal mice using a functionalized magnetic field (FMF) composed of positive- and negative-pulsed magnetic fields generated by electromagnetic coils. The FMNPs successfully reached the brain in a few minutes and showed evidence of blood-brain barrier (BBB) crossing. Moreover, the best FMF conditions were found for inducing the FMNPs to reach the cortex and hippocampus regions. Under the same FMF conditions, dextran-coated Fe3O4 magnetic nanoparticles (MNPs) loaded with osmotin (OMNP) were transported to the brains of Aβ1-42-treated mice. Compared with native osmotin, the OMNP potently attenuates Aβ1-42-induced synaptic deficits, Aβ accumulation, BACE-1 expression and tau hyperphosphorylation. This magnetic drug delivery approach can be extended to preclinical and clinical use and may advance the chances of success in the treatment of neurological disorders like AD in the future.

Original languageEnglish
Pages (from-to)10619-10632
Number of pages14
JournalNanoscale
Volume9
Issue number30
DOIs
Publication statusPublished - Aug 14 2017

Fingerprint

Brain
Neurodegenerative diseases
Magnetic fields
Nanoparticles
Drug delivery
Dextran
Dextrans
Nanotechnology
Amyloid
nile red

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Amin, F. U., Hoshiar, A. K., Do, T., Noh, Y., Shah, S. A., Khan, M. S., ... Kim, M. O. (2017). Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. Nanoscale, 9(30), 10619-10632. https://doi.org/10.1039/c7nr00772h

Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. / Amin, Faiz Ul; Hoshiar, Ali Kafash; Do, Ton; Noh, Yeongil; Shah, Shahid Ali; Khan, Muhammad Sohail; Yoon, Jungwon; Kim, Myeong Ok.

In: Nanoscale, Vol. 9, No. 30, 14.08.2017, p. 10619-10632.

Research output: Contribution to journalArticle

Amin, FU, Hoshiar, AK, Do, T, Noh, Y, Shah, SA, Khan, MS, Yoon, J & Kim, MO 2017, 'Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease', Nanoscale, vol. 9, no. 30, pp. 10619-10632. https://doi.org/10.1039/c7nr00772h
Amin, Faiz Ul ; Hoshiar, Ali Kafash ; Do, Ton ; Noh, Yeongil ; Shah, Shahid Ali ; Khan, Muhammad Sohail ; Yoon, Jungwon ; Kim, Myeong Ok. / Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. In: Nanoscale. 2017 ; Vol. 9, No. 30. pp. 10619-10632.
@article{f442fa54610c4ff2b7443f112ad6f7c6,
title = "Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disease, pathologically characterized by the accumulation of aggregated amyloid beta (Aβ) in the brain. Here, we describe for the first time the development of a new, pioneering nanotechnology-based drug delivery approach for potential therapies for neurodegenerative diseases, particularly AD. We demonstrated the delivery of fluorescent carboxyl magnetic Nile Red particles (FMNPs) to the brains of normal mice using a functionalized magnetic field (FMF) composed of positive- and negative-pulsed magnetic fields generated by electromagnetic coils. The FMNPs successfully reached the brain in a few minutes and showed evidence of blood-brain barrier (BBB) crossing. Moreover, the best FMF conditions were found for inducing the FMNPs to reach the cortex and hippocampus regions. Under the same FMF conditions, dextran-coated Fe3O4 magnetic nanoparticles (MNPs) loaded with osmotin (OMNP) were transported to the brains of Aβ1-42-treated mice. Compared with native osmotin, the OMNP potently attenuates Aβ1-42-induced synaptic deficits, Aβ accumulation, BACE-1 expression and tau hyperphosphorylation. This magnetic drug delivery approach can be extended to preclinical and clinical use and may advance the chances of success in the treatment of neurological disorders like AD in the future.",
author = "Amin, {Faiz Ul} and Hoshiar, {Ali Kafash} and Ton Do and Yeongil Noh and Shah, {Shahid Ali} and Khan, {Muhammad Sohail} and Jungwon Yoon and Kim, {Myeong Ok}",
year = "2017",
month = "8",
day = "14",
doi = "10.1039/c7nr00772h",
language = "English",
volume = "9",
pages = "10619--10632",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "30",

}

TY - JOUR

T1 - Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease

AU - Amin, Faiz Ul

AU - Hoshiar, Ali Kafash

AU - Do, Ton

AU - Noh, Yeongil

AU - Shah, Shahid Ali

AU - Khan, Muhammad Sohail

AU - Yoon, Jungwon

AU - Kim, Myeong Ok

PY - 2017/8/14

Y1 - 2017/8/14

N2 - Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disease, pathologically characterized by the accumulation of aggregated amyloid beta (Aβ) in the brain. Here, we describe for the first time the development of a new, pioneering nanotechnology-based drug delivery approach for potential therapies for neurodegenerative diseases, particularly AD. We demonstrated the delivery of fluorescent carboxyl magnetic Nile Red particles (FMNPs) to the brains of normal mice using a functionalized magnetic field (FMF) composed of positive- and negative-pulsed magnetic fields generated by electromagnetic coils. The FMNPs successfully reached the brain in a few minutes and showed evidence of blood-brain barrier (BBB) crossing. Moreover, the best FMF conditions were found for inducing the FMNPs to reach the cortex and hippocampus regions. Under the same FMF conditions, dextran-coated Fe3O4 magnetic nanoparticles (MNPs) loaded with osmotin (OMNP) were transported to the brains of Aβ1-42-treated mice. Compared with native osmotin, the OMNP potently attenuates Aβ1-42-induced synaptic deficits, Aβ accumulation, BACE-1 expression and tau hyperphosphorylation. This magnetic drug delivery approach can be extended to preclinical and clinical use and may advance the chances of success in the treatment of neurological disorders like AD in the future.

AB - Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disease, pathologically characterized by the accumulation of aggregated amyloid beta (Aβ) in the brain. Here, we describe for the first time the development of a new, pioneering nanotechnology-based drug delivery approach for potential therapies for neurodegenerative diseases, particularly AD. We demonstrated the delivery of fluorescent carboxyl magnetic Nile Red particles (FMNPs) to the brains of normal mice using a functionalized magnetic field (FMF) composed of positive- and negative-pulsed magnetic fields generated by electromagnetic coils. The FMNPs successfully reached the brain in a few minutes and showed evidence of blood-brain barrier (BBB) crossing. Moreover, the best FMF conditions were found for inducing the FMNPs to reach the cortex and hippocampus regions. Under the same FMF conditions, dextran-coated Fe3O4 magnetic nanoparticles (MNPs) loaded with osmotin (OMNP) were transported to the brains of Aβ1-42-treated mice. Compared with native osmotin, the OMNP potently attenuates Aβ1-42-induced synaptic deficits, Aβ accumulation, BACE-1 expression and tau hyperphosphorylation. This magnetic drug delivery approach can be extended to preclinical and clinical use and may advance the chances of success in the treatment of neurological disorders like AD in the future.

UR - http://www.scopus.com/inward/record.url?scp=85027051738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027051738&partnerID=8YFLogxK

U2 - 10.1039/c7nr00772h

DO - 10.1039/c7nr00772h

M3 - Article

AN - SCOPUS:85027051738

VL - 9

SP - 10619

EP - 10632

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 30

ER -